{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:41:48Z","timestamp":1790361708619,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.beha.2018.08.001","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T17:37:31Z","timestamp":1533663451000},"page":"199-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Optimizing initial therapy in DLBCL"],"prefix":"10.1016","volume":"31","author":[{"given":"Catherine","family":"Thieblemont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Meignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2018.08.001_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.08.001_bib2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.beha.2018.08.001_bib3","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2018.08.001_bib4","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.beha.2018.08.001_bib5","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-Cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.beha.2018.08.001_bib6","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.08.001_bib7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2018.08.001_bib8","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2018.08.001_bib9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.beha.2018.08.001_bib10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2018.08.001_bib11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2018.08.001_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2012-12-473389","article-title":"PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement","volume":"122","author":"Khan","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2018.08.001_bib13","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ajh.24169","article-title":"Outcome prediction by extranodal involvement, IPI, R\u2010IPI, and NCCN\u2010IPI in the PET\/CT and rituximab era: a Danish\u2013Canadian study of 443 patients with diffuse\u2010large B\u2010cell lymphoma","volume":"90","author":"El\u2010Galaly","year":"2015","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.beha.2018.08.001_bib14","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international workshop on interim-PET-scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"27","key":"10.1016\/j.beha.2018.08.001_bib15","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2018.08.001_bib16","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","article-title":"Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients","volume":"41","author":"Meignan","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"11","key":"10.1016\/j.beha.2018.08.001_bib17","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","article-title":"Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"41","author":"Sasanelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"15","key":"10.1016\/j.beha.2018.08.001_bib18","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin Canc Res"},{"issue":"12","key":"10.1016\/j.beha.2018.08.001_bib19","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med"},{"issue":"5870","key":"10.1016\/j.beha.2018.08.001_bib20","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"issue":"7089","key":"10.1016\/j.beha.2018.08.001_bib21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature04687","article-title":"A loss-of-function RNA interference screen for molecular targets in cancer","volume":"441","author":"Ngo","year":"2006","journal-title":"Nature"},{"issue":"7247","key":"10.1016\/j.beha.2018.08.001_bib22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"issue":"7332","key":"10.1016\/j.beha.2018.08.001_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.beha.2018.08.001_bib24","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMra0807082","article-title":"Aggressive lymphomas","volume":"362","author":"Lenz","year":"2010","journal-title":"N Engl J Med"},{"issue":"Suppl 52","key":"10.1016\/j.beha.2018.08.001_bib25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/hon.2437_3","article-title":"Interim report from a phase 2 multicentre study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory B-cell non-Hodgkin lymphomas","volume":"35","author":"Morschhauser","year":"2017","journal-title":"Hematol Oncol"},{"issue":"30","key":"10.1016\/j.beha.2018.08.001_bib26","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1073\/pnas.1305656110","article-title":"PTEN loss defines a PI3K\/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma","volume":"110","author":"Pfeifer","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"36","key":"10.1016\/j.beha.2018.08.001_bib27","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.beha.2018.08.001_bib28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2018.08.001_bib29","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.08.001_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmoldx.2015.01.007","article-title":"Accurate classification of germinal center B-Cell-Like\/Activated B-Cell-Like diffuse large B-Cell lymphoma using a simple and rapid reverse transcriptase-multiplex ligation-dependent probe amplification assay: a calym study","author":"Mareschal","year":"2015","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.beha.2018.08.001_bib31","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.08.001_bib32","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1182\/blood-2005-10-4222","article-title":"Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study","volume":"107","author":"Winter","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.08.001_bib33","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9880","key":"10.1016\/j.beha.2018.08.001_bib34","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.beha.2018.08.001_bib35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9806","key":"10.1016\/j.beha.2018.08.001_bib36","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Groupe d'Etude des Lymphomes de l'Adulte. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial","volume":"378","author":"Recher","year":"2011","journal-title":"Lancet"},{"issue":"35","key":"10.1016\/j.beha.2018.08.001_bib37","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1200\/JCO.2013.54.9493","volume":"32","author":"Molina","year":"2014","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2018.08.001_bib38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.V128.22.469.469","article-title":"Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB\/Alliance 50303","volume":"128","author":"Wilson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.08.001_bib39","article-title":"Highdose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults","volume":"1","author":"Greb","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.beha.2018.08.001_bib40","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","article-title":"Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)","volume":"13","author":"Schmitz","year":"2012","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.beha.2018.08.001_bib41","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2018.08.001_bib42","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14860","article-title":"Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients","volume":"179","author":"Pfreundschuh","year":"2017","journal-title":"Br J Haematol"},{"issue":"27","key":"10.1016\/j.beha.2018.08.001_bib43","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2018.08.001_bib44","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DeltaSUVmax","volume":"40","author":"Itti","year":"2013","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"20","key":"10.1016\/j.beha.2018.08.001_bib45","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"PETAL trial investigators. Positron emission tomography-guided therapy of aggressive non-hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2018.08.001_bib46","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","article-title":"FDG-PET\u2013driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study","volume":"130","author":"Casasnovas","year":"2017","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.beha.2018.08.001_bib47","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-Cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2018.08.001_bib48","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3324\/haematol.2013.100818","article-title":"R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes","volume":"99","author":"Seymour","year":"2014","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.beha.2018.08.001_bib49","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2018.08.001_bib50","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.beha.2018.08.001_bib51","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V126.23.811.811","article-title":"Randomized phase 2 openlabel study of R-CHOP and bortezomib in patients (Pts) with untreated non-germinal center B-cell-like (non-GCB) subtype diffuse large cell lymphoma (DLBCL): results from the PYRAMID trial (NCT00931918)","volume":"126","author":"Leonard","year":"2015","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.beha.2018.08.001_bib52","first-page":"130","article-title":"Differential efficacy of bortezomib in subtypes of diffuse large B-cell lymphoma (DLBL): a prospective randomised study stratified by transcriptome profiling: REMoDL-B","volume":"35","author":"Davies","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.beha.2018.08.001_bib53","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.beha.2018.08.001_bib54","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20- positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.beha.2018.08.001_bib55","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2018.08.001_bib56","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.beha.2018.08.001_bib57","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A phase 2\/3 multicenter, randomized, open-label study of lenalidomide vs investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.beha.2018.08.001_bib58","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","article-title":"Fondazione Italiana Linfomi. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial","volume":"15","author":"Vitolo","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.beha.2018.08.001_bib59","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2018.08.001_bib60","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.beha.2018.08.001_bib61","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1200\/JCO.2015.65.7171","article-title":"Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma","volume":"34","author":"Crump","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1016\/j.beha.2018.08.001_bib62","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2016.34.15_suppl.7506","article-title":"PILLAR-2: a randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL)","volume":"34","author":"Witzig","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2018.08.001_bib63","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3324\/haematol.2015.125344","article-title":"AGMT-NHL13 Investigators. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial","volume":"100","author":"Jaeger","year":"2015","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.beha.2018.08.001_bib64","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S1470-2045(11)70140-1","article-title":"Prevention of CNS relapse in diffuse large B-cell lymphoma","volume":"12","author":"Kridel","year":"2011","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.beha.2018.08.001_bib65","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-Cell lymphoma treated with r-chop","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.08.001_bib66","series-title":"Analysis of CNS relapses risk factors in a population of 1615 upfront DLBCL patients treated in LYSA protocols LNH03 and lnh07-3B","author":"Bernard","year":"2018"},{"key":"10.1016\/j.beha.2018.08.001_bib67","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejca.2016.12.029","article-title":"The number of extranodal sites assessed by PET\/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: an international multicenter study of 1532 patients treated with chemoimmunotherapy","volume":"75","author":"El-Galaly","year":"2017","journal-title":"Eur J Cancer"},{"issue":"44","key":"10.1016\/j.beha.2018.08.001_bib68","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001978","article-title":"Prediction of central nervous system relapse of diffuse large B-Cell lymphoma using pretherapeutic [18F]2-Fluoro-2-Deoxyglucose (FDG) positron emission tomography\/computed tomography","volume":"94","author":"Song","year":"2015","journal-title":"Medicine (Baltim)"},{"issue":"23","key":"10.1016\/j.beha.2018.08.001_bib69","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.08.001_bib70","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.08.001_bib71","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.08.001_bib72","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.08.001_bib73","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood-2015-10-676700","article-title":"Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL","volume":"127","author":"Savage","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2018.08.001_bib74","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3109\/10428194.2014.977884","article-title":"Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study","volume":"56","author":"Fleury","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 5","key":"10.1016\/j.beha.2018.08.001_bib75","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"ESMO Guidelines Committee. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.beha.2018.08.001_bib76","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.blre.2011.12.001","article-title":"CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?","volume":"26","author":"Siegal","year":"2012","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.beha.2018.08.001_bib77","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/bjc.2014.405","article-title":"A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma","volume":"111","author":"Cheah","year":"2014","journal-title":"Br J Cancer"},{"issue":"18","key":"10.1016\/j.beha.2018.08.001_bib78","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1002\/cncr.25278","article-title":"Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma","volume":"116","author":"Abramson","year":"2010","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.beha.2018.08.001_bib79","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41408-018-0097-0","article-title":"CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies","volume":"8","author":"Ayed","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.beha.2018.08.001_bib80","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2018.08.001_bib81","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2003.11.141","article-title":"Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group","volume":"21","author":"Zucca","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2018.08.001_bib82","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/bjh.14325","article-title":"Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement","volume":"175","author":"El-Galaly","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2018.08.001_bib83","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bjh.12753","article-title":"A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era","volume":"165","author":"Hosein","year":"2014","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.beha.2018.08.001_bib84","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2018.08.001_bib85","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11864-018-0555-8","article-title":"Extranodal diffuse large B cell lymphoma: molecular features, prognosis, and risk of central nervous system recurrence","volume":"19","author":"Ollila","year":"2018","journal-title":"Curr Treat Options Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:03:34Z","timestamp":1571702614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692618300574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1521692618300574"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2018.08.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing initial therapy in DLBCL","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2018.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}